On Jun. 22, 2021, the National Research Council of Canada (NRC) announced it had completed construction of the new Biologics Manufacturing Centre on the Royalmount site in Montr�al, Qu�bec.

Once fully licensed and operational, the Biologics Manufacturing Centre will provide full end-to-end manufacturing capabilities. With approximately 5,400 square metres (58,000 square feet) of space, it has a production capacity of approximately 24 million doses of a vaccine per year, varying based on the specific vaccine requirements.